Bronchiectasis is a heterogeneous condition and may be encountered as a stand-alone pulmonary disease by primary care clinicians and specialists in pulmonary medicine. Bronchiectasis sometimes ...

Please provide your email address to receive an email when new articles are posted on . Adults with a long-term smoking history suspected to have bronchiectasis faced an elevated mortality risk ...

BRONCHIECTASIS is protean in its expressions as it is sometimes obscure in its origin. The clinical picture varies in individual patients, but common to the severer cases is a history of harassing, ...

Bronchiectasis is a lung condition that causes a persistent cough and excess phlegm, or sputum. It is a permanent condition that gets worse over time. It can be fatal. The bronchi dilate, usually ...

Please provide your email address to receive an email when new articles are posted on . The population-based cohort study included 3,858,422 participants from the 2009 National Health Screening ...

We introduced domiciliary intravenous (IV) antibiotic therapy in patients with bronchiectasis to promote patient-centred domiciliary treatment instead of hospital inpatient treatment. A total of 116 ...

Bronchiectasis is a chronic condition of the respiratory system that is due to abnormal widening of the airways as a consequence of an initial damaging factor. The bronchi, located between the trachea ...

WEDNESDAY, Aug. 13, 2025 (HealthDay News) — For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has approved Insmed’s daily pill ...

Bronchiectasis is a chronic condition of the respiratory system, in which there is abnormal widening of the airways due to an initial damaging factor. This in turn reduces the ability of the bronchi ...

Bronchiectasis is a condition where the bronchial tubes of your lungs are permanently damaged, widened, and thickened. These damaged air passages allow bacteria and mucus to build up and pool in your ...

Bronchiectasis hospitalizations have higher mortality and costs than COPD and asthma, with a median stay of 5 days and costs of $50,393. During the COVID-19 pandemic, bronchiectasis hospitalizations ...